Skip to main content
Addgene

Lenti-MAPK14
(Plasmid #200973)

Print

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 200973 Standard format: Plasmid sent in bacteria as agar stab 1 $89
Add to Cart

Backbone

  • Vector backbone
    pEZ-Lv105
  • Backbone manufacturer
    Genecopoeia
  • Backbone size w/o insert (bp) 8039
  • Total vector size (bp) 9122
  • Vector type
    Mammalian Expression, Lentiviral
  • Selectable markers
    Puromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    mitogen-activated protein kinase 14 (MAPK14)
  • Alt name
    p38 alpha
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    1083
  • GenBank ID
    NM_001315 NM_001315
  • Entrez Gene
    MAPK14 (a.k.a. CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2, PRKM14, PRKM15, RK, SAPK2A, p38, p38ALPHA)
  • Promoter CMV

Cloning Information

  • Cloning method Unknown
  • 5′ sequencing primer GCGGTAGGCGTGTACGGT
  • 3′ sequencing primer ATTGTGGATGAATACTGCC
    • (Common Sequencing Primers)

Resource Information

  • A portion of this plasmid was derived from a plasmid made by
    Genecopoeia

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

Please visit https://doi.org/10.1101/2022.10.16.512438 for bioRxiv preprint.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    Lenti-MAPK14 was a gift from Jason Sheltzer (Addgene plasmid # 200973 ; http://n2t.net/addgene:200973 ; RRID:Addgene_200973)

  • For your References section:

    Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor. Bhattacharjee D, Bakar J, Chitnis SP, Sausville EL, Ashtekar KD, Mendelson BE, Long K, Smith JC, Heppner DE, Sheltzer JM. Cell Chem Biol. 2023 Oct 19;30(10):1211-1222.e5. doi: 10.1016/j.chembiol.2023.09.013. Epub 2023 Oct 11. 10.1016/j.chembiol.2023.09.013 PubMed 37827156
Related items: